

業 績 目 録（令和 5 年）

大学院科目名：呼吸器内科学

(A-a) 英文著書

なし

(A-b) 和文著書

なし

(B-a) 英文総説

1. Morita-Tanaka S, Yamada T, Takayama K.
The landscape of cancer cachexia in advanced non-small cell lung cancer:
a narrative review
Transl Lung Cancer Res. 12(1):168-180. 2023 (IF=4.0)
2. Sumiyoshi A, Fujii H, Okuma Y
Targeting microbiome, drug metabolism, and drug delivery in oncology
Adv Drug Deliv Rev. 199:114902. 2023 (IF=15.2)
3. Fukuda A, Yoshida T
Treatment of advanced ALK-rearranged NSCLC following second-generation
ALK-TKI failure
Expert Rev Anticancer Ther. 29:1-11. 2023 (IF=2.9)

(B-b) 和文総説

1. 岩破 将博, 高山 浩一
ゲノム医療
臨牀と研究
大道学館出版部 100(8), 967-972 2023
2. 森本 健司, 高山 浩一
肺癌における周術期の免疫療法
臨牀外科 医学書院 Vol. 78 No. 1 2023
3. 森田 理美
がん悪液質の薬物療法
呼吸器内科 科学評論社
43(2), 213-218 2023

4. 立花 佑介, 高山 浩一
がん悪液質薬物療法の進歩
癌と化学療法 癌と化学療法社
50(8), 873-877 2023

5. 澤田 凌, 金 永学
肝障害患者の肺癌薬物療法-3 つの STEP で考える-
呼吸器内科 科学評論社
43, 148-154 2023

6. 金子 美子, 高山 浩一
サルコイドーシスの肺病変
京府医大誌 京都府立医科大学
132 (4)251-258 2023

(C-a) 英文原著

1. Sakakida T, Ishikawa T, Doi T, Morita R, Kataoka S, Miyake H, Yamaguchi K, Moriguchi M, Sogame Y, Yasuda H, Iwasaku M, Konishi H, Takayama K, Itoh Y.
Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan
J Gastroenterol. 58(6):575-585, 2023 (IF=6.9)

2. Shukuya T, Takahashi K, Shintani Y, Miura K, Sekine I, Takayama K, Inoue A, Okamoto I, Kiura K, Kawaguchi T, Yamamoto N, Miyaoka E, Yoshino I, Date H.
Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study
J Cachexia Sarcopenia Muscle. 14(3):1274-1285, 2023 (IF=9.4)

3. Kanbayashi Y, Taguchi T, Ishikawa T, Otsuji E, Takayama K
Risk factors of capecitabine-induced hand-foot syndrome: a single-institution, retrospective study
Oncology. 101(7):407-414, 2023 (IF=2.5)

4. Takayama K, Takiguchi T, Komura N, Naito T.

Efficacy and safety of anamorelin in patients with cancer cachexia: Post-hoc subgroup analyses of a placebo-controlled study
Cancer Med 2023 12(3):2918–2928 (IF=2.9)

5. Uda S, Yamada T, Yoshimura A, Goto Y, Yoshimine K, Nakamura Y, Shiotsu S, Yokoi T, Tamiya N, Kimura H, Chihara Y, Umeda Y, Izumi M, Takeda T, Yamada T, Hibino M, Hiranuma O, Ito K, Okada A, Osugi S, Takemura Y, Ishii H, Chibana K, Hasegawa I, Morimoto Y, Iwasaku M, Tokuda S, Takayama K.

Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study
Transl Lung Cancer Res. 11(9):1847–1857. 2023 (IF=4.0)

6. Taniguchi H, Akagi K, Dotsu Y, Yamada T, Ono S, Imamura E, Gyotoku H, Takemoto S, Yamaguchi H, Sen T, Yano S, Mukae H.

Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK-rearranged lung cancer
Cancer Sci. 114(1):164–173. 2023 (IF=4.5)

7. Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, Matsui Y, Nakamura R, Ishida M, Kawachi H, Yoneda K, Hosoya K, Tsuji T, Ozasa H, Yoshimura A, Iwasaku M, Kim YH, Horinaka M, Sakai T, Utsumi T, Shiotsu S, Takeda T, Katayama R, Takayama K.

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
NPJ Precis Oncol. 26;7(1):12. 2023 (IF=6.8)

8. Hata T, Sakaguchi C, Hirano K, Kobe H, Ishida M, Nakano T, Tachibana Y, Tamiya N, Shiotsu S, Takeda T, Yamada T, Yokoyama T, Tsuchiya M, Nagasaka Y.

Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study
J Cancer Res Clin Oncol. 149(6):2475–2482. 2023 (IF=2.7)

9.Tanimura K, Uchino J, Kimura H, Hiranuma O, Chihara Y, Tanzawa S, Takumi C, Kita T, Inoue K, Minato K, Takemoto S, Nakao A, Yoshimura K, Takayama K.

Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases; A Multicenter, Open-Label Single-Arm Phase II Trial

Oncologist. 28(6):551-e454 2023 (IF=4.8)

10.Yoshimura A, Yamada T, Serizawa M, Uehara H, Tanimura K, Okuma Y, Fukuda A, Watanabe S, Nishioka N, Takeda T, Chihara Y, Takemoto S, Harada T, Hiranuma O, Shirai Y, Shukuya T, Nishiyama A, Goto Y, Shiotsu S, Kunimasa K, Morimoto K, Katayama Y, Suda K, Mitsudomi T, Yano S, Kenmotsu H, Takahashi T, Takayama K

High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib

Cancer Sci.114(2):606-618.2023 (IF=4.5)

11.Takeda T, Yamada T, Kunimatsu Y, Tanimura K, Morimoto K, Shiotsu S, Chihara Y, Okada A, Horiuchi S, Hibino M, Uryu K, Honda R, Yamanaka Y, Yoshioka H, Kurata T, Takayama K.

Age-stratified analysis of first-line chemoimmunotherapy for extensive-stage small cell lung cancer: Real-world evidence from a multicenter retrospective study

Cancers (Basel). 15(5):1543.2023 (IF=4.5)

12.Ishida M, Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, Tamiya N, Chihara Y, Takemura Y, Yamada T, Kanda H, Iwasaku M, Tokuda S, Kim YH, Takayama K.

Early tumor shrinkage as a predictor of favorable treatment outcomes in patients with extensive stage-small cell lung cancer who received programmed cell death-ligand 1 inhibitor plus platinum-etoposide chemotherapy: A prospective observational study

JTO Clin Res Rep. 4(4):100493. 2023 (IF=3.0)

13.Noguchi R, Yoshimura A, Uchino J, Takeda T, Chihara Y, Ota T, Hiranuma O, Gyotoku H, Takayama K, Kondo T.

Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations
Proteomes. 11(1):6. 2023 (IF=4.0)

14. Fukuda A, Yoshida T, Yagishita S, Shiotsuka M, Kobayashi O, Iwata S, Umeguchi H, Yanagida M, Irino Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamada A, Yamamoto N, Ohe Y.

Real-world Data on the Incidence of Coronavirus Disease (COVID-19) in Patients With Advanced Thoracic Cancer During the Early Phase of the Pandemic in Japan

Anticancer Res. 43(2):919-926 2023 (IF=1.6)

15. Katayama Y, Yamada T, Morimoto K, Fujii H, Morita S, Tanimura K, Takeda T, Okada A, Shiotsu S, Chihara Y, Hiranuma O, Yamada T, Ota T, Harada T, Hasegawa I, Yoshimura A, Iwasaku M, Tokuda S, Kim YH, Takayama K.

TTF-1 expression and clinical outcomes of combined chemoimmunotherapy in patients with advanced lung

adenocarcinoma: A prospective observational study

JTO Clin Res Rep. 7;4(4):100494. 2023 (IF=3.0)

16. Nakamura R, Yamada T, Tanaka S, Sasada A, Shiotsu S, Tani N, Takeda T, Chihara Y, Hirai S, Takemura Y, Yoshimura A, Morimoto K, Iwasaku M, Tokuda S, Kim YH, Takayama K.

Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non-small cell lung cancer
Cancer Med 12(8):9097-9105. 2023 (IF=2.9)

17. Morita-Tanaka S, Miyagawa-Hayashino A, Yamada T, Matsui Y, Morimoto K, Hiranuma O, Masuzawa N, Yoshimura A, Iwasaku M, Tokuda S, Kaneko Y, Kim YH, Konishi E, Takayama K.

Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer

Support Care Cancer. 31(5):308. 2023 (IF=2.8)

18. Tanizaki S, Matsumoto K, Tamiya A, Taniguchi Y, Matsuda Y, Uchida J, Ueno K, Kawachi H, Tamiya M, Yanase T, Suzuki H, Okishio K.
Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study
Eur J Clin Pharmacol. 79(4): 503–511 2023 (IF=2.8)

19. Hata T, Sakaguchi C, Hirano K, Kobe H, Ishida M, Nakano T, Tachibana Y, Tamiya N, Shiotsu S, Takeda T, Yamada T, Yokoyama T, Tsuchiya M, Nagasaka Y.
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study
Thorac Cancer. 2023 Apr;14(11):1004–1011. 2023 (IF=2.3)

20. Nakamura R, Fujii H, Yamada T, Matsui Y, Yaoi T, Honda M, Tanaka N, Miyagawa-Hayashino A, Yoshimura A, Morimoto K, Iwasaku M, Tokuda S, Kim YH, Konishi E, Itoh K, Takayama K.
Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors
JTO Clin Res Rep. 4(6):100525. 2023 (IF=3.0)

21. Sakakida T, Ishikawa T, Doi T, Morita R, Kataoka S, Miyake H, Yamaguchi K, Moriguchi M, Sogame Y, Yasuda H, Iwasaku M, Konishi H, Takayama K, Itoh Y.
Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan
J Gastroenterol. 58(6):575–585. 2023 (IF=6.9)

22. Morimoto K, Yamada T, Sawada R, Azuma K, Goto Y, Harada T, Shiotsu S, Tamiya N, Chihara Y, Takeda T, Hiranuma O, Hasegawa I, Tanaka S, Yoshimura A, Iwasaku M, Tokuda S, Kim YH, Takayama K.
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in

patients with epidermal growth factor-mutant non-small cell lung cancer
Cancer Immunol Immunother. 72(6):1699–1707. 2023 (IF=4.6)

23. Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, Tamiya N, Chihara Y, Takemura Y, Yamada T, Kanda H, Ishida M, Yoshimura A, Iwasaku M, Tokuda S, Kim YH, Takayama K.

Prospective observational study evaluating the prognostic value of the G8 screening tool for extensive-stage small cell lung cancer patients who received programmed death-ligand 1 inhibitor plus platinum-etoposide chemotherapy

Drugs Aging. 40(6):563–571. 2023 (IF=3.4)

24. Iwasaku M, Uchino J, Chibana K, Tanzawa S, Yamada T, Tobino K, Uchida Y, Kijima T, Nakatomi K, Izumi M, Tamiya N, Kimura H, Fujita M, Honda R, Takumi C, Yamada T, Kaneko Y, Kiyomi F, Takayama K.

Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial

Cancer Med. 12(14):15117–15127. 2023 (IF=2.9)

25. Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K.

Concomitant proton pump inhibitor use with pembrolizumab monotherapy vs immune checkpoint inhibitor plus chemotherapy in patients with non-small cell lung cancer

JAMA Netw Open. 6(7): e2322915. 2023 (IF=10.5)

26. Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Tamiya N, Goto Y, Kanda H, Chihara Y, Kunimatsu Y, Katayama Y, Iwasaku M, Tokuda S, Takayama K

Clinical efficacy and safety of first- or second-generation EGFR-TKIs after osimertinib resistance for EGFR mutated lung cancer: A prospective exploratory study

Target Oncol. 18(5):657–665. 2023 (IF=4.4)

27. Tanimura K, Takeda T, Yoshimura A, Honda R, Goda S, Shiotsu S, Fukui M, Chihara Y, Uryu K, Takei S, Katayama Y, Hibino M, Yamada T, Takayama K.

Predictive value of modified Glasgow prognostic score and persistent inflammation among patients with non-small cell lung cancer treated with durvalumab consolidation after chemoradiotherapy: A multicenter retrospective study

Cancers (Basel). 15(17):4358. 2023 (IF=4.5)

28. Minamibata A, Kono Y, Arimoto T, Marunaka Y, Takayama K.

Variability of serum CYFRA 21 - 1 and its susceptibility to clinical characteristics in individuals without cancer: a 4-year retrospective analysis

BMC Pulm Med. 23(1):344 2023 (IF=2.6)

(C-c) 和文原著

なし

(D) 学会発表

I) 招待講演、特別講演、教育講演等

1. 山田忠明

遺伝子パネル検査の課題

第 63 回日本呼吸器学会総会 2023 年 4 月 東京

II) シンポジウム、ワークショップ、パネルディスカッション等

1. 高山浩一

がん悪液質の総論とグレリン様作動薬

第 26 回日本病態栄養学会年次学術集会 2023 年 1 月 京都

2. 高山浩一

がん悪液質の包括的治療

第 20 回日本臨床腫瘍学会学術集会 2023 年 3 月 福岡

III) 国際学会における一般発表

1. AACR Annual Meeting 2023 Apr 14-19, USA

- Yamada T, Nakamura R, Fujii H, Yaoi T, Itoh K, Tokuda S, Takayama K.
Tumor heterogeneity via AXL activation on primary resistance to EGFR tyrosine kinase inhibitors in EGFR mutated lung cancer.
2. Tokuda S, Onoi K, Yamada T, Takayama K.
Effects of interstitial pressure on lung cancer cells.
 3. Morimoto K, Yamada T, Tokuda S, Takayama K.
Clinical impact of p53 and AXL immunostaining on the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor mutant non-small cell lung cancer.
 4. Katayama Y, Yamada T, Ozasa H, Tokuda S, Takayama K.
EGFR activation via c-Jun axis promotes adaptive resistance to third generation ALK-TKI lorlatinib in ALK-rearranged non-small cell lung cancer cells.
 5. ASCO breakthrough 2023 Aug 3-5 (Fukuda A, Yoshida T, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Ohe Y.
Differential therapeutic benefit of platinum-doublet chemotherapies with ICIs based on the classification by combined with smoking status and PD-L1 expression in advanced NSCLC patients.
 6. IASLC2023 World Conference on Lung Cancer 2023 Sep 9-12, Singapore
Yamada T, Morimoto K, Azuma K, Goto Y, Harada T, Shiotsu S, Tamiya N, Chihara Y, Takeda T, Hiranuma O, Hasegawa I, Takayama K.
Roles of p53 and AXL expressions on the efficacy of ICI-based therapy in patients with EGFR mutated lung cancer after osimertinib .
 7. Katayama Y, Yamada T, Morimoto K, Takeda T, Okada A, Shiotsu S, Chihara Y, Hiranuma O, Yamada T, Ota T, Harada T, Hasegawa I, Takayama K.
Clinical impact of TTF-1 for combined chemoimmunotherapy efficacy in lung adenocarcinoma: A multicenter prospective study.
 8. Matui Y, Yamada T, Takayama K.
Inhibition of AXL and Mcl-1 contributes to eradicating tolerance to EGFR-TKI Lazertinib in lung cancer cells expressing mutant EGFR.

E 研究助成（競争的研究助成金）

総額 1,036 万円（全ての小計の合計）

公的助成

代表 小計 980 万円

1. AMED 革新的がん医療実用化研究事業

高齢者進行非小細胞肺癌/膵がんに対する早期栄養・運動介入とアナモレリン塩酸塩の併用療法の多施設共同ランダム化第二相試験 令和5年度
高山浩一（代表） 助成金額 580 万円

2. 文部科学省科学研究費 基盤C 令和5年度～令和7年度

肺癌低酸素環境適応機構に起因した治療抵抗性の解明と新規標的治療法開発
山田忠明（代表） 助成金額 90 万円

3. 文部科学省科学研究費 研究活動スタート支援 令和4年度～令和5年度

分子標的薬の初期抵抗性に関わるキナーゼシグナル伝達の解明とその克服治療法開発

森本健司（代表） 助成金額 110 万円

4. 文部科学省科学研究費 若手研究 令和5年度～令和7年度

新たな視点で肺癌患者の療養実態に迫り、医療の課題を解明する研究
岩破将博（代表） 助成金額 170 万円

5. 文部科学省科学研究費 若手研究 令和5年度～令和7年度

Steven-Johnson 症候群の慢性期粘膜障害に関わる好中球機能の検討
金子美子（代表） 助成金額 30 万円

財団等からの助成

代表（総額） 56 万円

1. ヤンセンファーマ株式会社 研究者主導研究 令和4年度

EGFR 変異肺癌におけるラゼルチニブ治療抵抗性の機構解明を目指した研究

山田忠明（代表） 助成金額 56 万円